A drug long-used to counter the negative effects of chemotherapy has won US Food and Drug Administration (FDA) approval for use in treating the nasty effects of exposure to radiation following a nuclear disaster. Known commercially as Neupogen, the drug has been shown to work by shielding the body's white blood cells to heighten a patient's chances of survival.
A research team at Lund University in Sweden has conducted a study to
test the effectiveness of tomosynthesis breast screening against more
conventional mammograms. The results are promising, showing the new
technique to be better at detecting tumors, as well as being a more
comfortable experience for the patient.
A key battleground in the fight against cancer has been the development of vaccines to stop tumors taking hold. These are intended to kick the body's own immune system into action to fend off the cancerous cells, with immunotherapy drugs for melanomas, prostate and lung cancer all emerging in recent years. But one hurdle oncologists are yet to tackle with any great success is a vaccine for breast cancer. New research now suggests this mightn't be all that far away, with the discovery that loading cancer antigens into silicon microparticles serves to greatly boost the immune response.
Researchers at the University of California, Davis have developed and tested a molecule that has the ability to disrupt the body's regulation of cancer cells, causing the cells to self-destructing rather than multiply. The method was found to be effective when tackling dormant brain cancer cells that existing treatments are ineffective at eradicating.